Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
about
Targeting gastrointestinal stromal tumors: the role of regorafenibEmerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future DirectionsCombining radiotherapy with sunitinib: lessons (to be) learnedClinical practice guidelines for patients with gastrointestinal stromal tumor in TaiwanSunitinib: the antiangiogenic effects and beyondSunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectivesStrategies for modern biomarker and drug development in oncology.Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience.Phase II study of sunitinib malate in patients with recurrent high-grade glioma.Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancerPhase II open-label study of sunitinib in patients with advanced breast cancer.Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumorPopulation Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal TumorUK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trialsNCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours.Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.Clinical and therapeutic considerations of GISTContinuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).A gist of gastrointestinal stromal tumors: A review.GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)Succinate dehydrogenase-deficient gastrointestinal stromal tumors.Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutationsCirculating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failureVatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study
P2860
Q26747162-3F75E43E-E3D6-4953-9BD8-EB100BCFC6EBQ26799387-18C18340-2FCB-4640-9FAE-D0421DA5982BQ26800587-F74A949F-3CEB-4F82-A2F8-875A1673CF23Q27027632-63A9F6FD-946B-4DB9-B5B6-49081EEBC395Q28066499-A5C880A7-9A91-48C5-A489-E07EEF564111Q28069560-CDB9B586-260E-4AEA-8DA3-191F92BEB6ACQ30590270-02A9E25B-8CF7-4B22-8EC4-9AC132DC78ECQ31112956-2B92487E-B8F5-4BEB-AEF7-54A70F5BF43CQ33392046-947766F6-0263-439F-9D82-575A6B7DB582Q33392955-A7BE03CA-3DFD-4C8D-929B-7ECF7F8CD9CAQ33394774-93B14521-B46D-4357-8BE2-4909C47B4599Q33395780-C7D6BD65-D435-4620-867D-90152DC07706Q33397590-895E632B-1035-4AD4-B556-918262216365Q33403848-B475E168-F0BC-4C1F-A3AA-44C8D3BA4A5DQ33409913-BE6F32AF-34DD-4270-81B3-BE6336C633F4Q33420123-B2666176-2092-4934-8C6B-0A7A07579351Q33425872-83AF37C9-878E-471A-BB38-BEE156873412Q33432047-861CFE13-DE2D-472E-97B9-8DEE6443AF8FQ33612778-E6AF1064-E8B0-45DD-9B39-DB930ECB9713Q33613666-A7340968-9E4E-48F6-A74D-978AEE59320BQ33633424-B9B7F6A9-D56D-455B-BFB8-F8F8D822D164Q33644791-FCF48E98-71D6-4EAF-B3E2-A483C4D560E7Q33648995-7D4535EC-48F5-4CD3-AB17-33DA3FC83658Q33794403-D3A6F5AC-F8B1-42B3-8F09-7E61326B71D9Q33849805-91449A36-E2F2-49B9-A9D5-E6A5ECB4D0E8Q33921067-8BB2D6EC-59D4-452A-A5E9-ECEF332C1246Q34048307-27CF9909-71D7-49A6-9DC5-03551A70EAE7Q34052411-2C23FAA1-2F23-451E-9222-5CD37257E511Q34141825-B3718157-2AC7-43DA-8A93-87D0BDD4E18FQ34202396-EF18B49B-6F8B-4AC7-908E-13ED17ECC74FQ34341168-696F4354-28E0-4A45-9E59-DC3304BAF954Q34617414-C844B136-D578-4E69-A43F-512F8B7E1836Q34654203-1D5741FB-1E2B-48A3-A7CE-AA9E1C023510Q34664305-11A693B6-B22A-4B3C-B72A-B0F7E38978C3Q34668378-00784133-F413-4B86-8451-0BECD00D75E7Q34714310-2F823CE8-B0E9-40C7-8AA1-5084A8FB2926Q34804754-F79BF33E-8B33-4BBE-AE49-33931663A87DQ35001643-FDDD3961-7DEE-4DF4-BE1D-FAE55510A5ABQ35034603-5770443A-1302-4746-A915-C3176096817AQ35114038-8B18DF6B-8846-4E07-A12F-4EE9EA60B34A
P2860
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Clinical evaluation of continu ...... tumour after imatinib failure.
@ast
Clinical evaluation of continu ...... tumour after imatinib failure.
@en
Clinical evaluation of continu ...... tumour after imatinib failure.
@nl
type
label
Clinical evaluation of continu ...... tumour after imatinib failure.
@ast
Clinical evaluation of continu ...... tumour after imatinib failure.
@en
Clinical evaluation of continu ...... tumour after imatinib failure.
@nl
prefLabel
Clinical evaluation of continu ...... tumour after imatinib failure.
@ast
Clinical evaluation of continu ...... tumour after imatinib failure.
@en
Clinical evaluation of continu ...... tumour after imatinib failure.
@nl
P2093
P50
P1476
Clinical evaluation of continu ...... tumour after imatinib failure.
@en
P2093
C S Harmon
G D Demetri
J A Morgan
P G Casali
P Stephenson
S E Deprimo
P304
P356
10.1016/J.EJCA.2009.02.011
P577
2009-03-11T00:00:00Z